Stockreport

Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology

FIVE PRIME THERAPEUTICS  (FPRX) 
Last five prime therapeutics earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.fiveprime.com/investor-relations
PDF Phase 1 data illustrates the therapeutic potential of bemarituzumab as a novel approach to treating patients with FGFR2b-overexpressing gastric and gastroesophageal junc [Read more]